AADI - Aadi Bioscience launches rare cancer therapy Fyarro

Aadi Bioscience (NASDAQ:AADI) launched its first proprietary product, Fyarro to treat a rare form of cancer. In November 2021, the FDA approved Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use to treat patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). The company also launched Aadi Assist as its comprehensive patient support program, which offers resources designed to connect patients with co-pay assistance, referrals, verification of benefits and to ensure access to the drug as quickly and efficiently as possible.

For further details see:

Aadi Bioscience launches rare cancer therapy Fyarro